Form 8-K

8-K — Immix Biopharma, Inc.

Accession: 0001493152-26-024872

Filed: 2026-05-21

Period: 2026-05-21

CIK: 0001873835

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-1.1 (ex1-1.htm)

EX-5.1 (ex5-1.htm)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex5-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001873835

2026-05-21

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

WASHINGTON,

DC 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of

the

Securities Exchange Act of 1934

Date

of report (Date of earliest event reported): May 21, 2026

IMMIX

BIOPHARMA, INC.

(Exact

Name of Registrant as Specified in Its Charter)

Delaware

001-41159

45-4869378

(State

or Other Jurisdiction

Incorporation)

(Commission

File

Number)

(I.R.S.

Employer

Identification

Number)

11400

West Olympic Blvd., Suite 200

Los

Angeles, CA 90064

(Address

of principal executive offices)

(310)

651-8041

(Registrant’s

telephone number, including area code)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under

any of the following provisions.

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

Securities

registered pursuant to Section 12(b)of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock, par value of $0.0001 per share

IMMX

The

Nasdaq Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☒

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

8.01. Other Events.

May 21, 2026, Immix Biopharma, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the

“Underwriting Agreement”) with Morgan Stanley & Co. LLC, as representative of the several underwriters named in Schedule

I thereto, pursuant to which the Company agreed to issue and sell, in an underwritten offering (the “Offering”), an

aggregate of 16,778,524 shares of its common stock, par value $0.0001 per share (the “Shares”) at a public offering

price of $8.94 per share.

The

Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing,

and customary indemnification obligations of the Company, including for liabilities under the Securities Act of 1933, as amended (the

“Securities Act”).

The

Company estimates that the net proceeds to the Company from the Offering, after deducting underwriting discounts and commissions, and

estimated offering expenses, are expected to be approximately $140.65 million. The Offering is expected to close on May 22, 2026,

subject to the satisfaction of customary conditions.

The

Offering is being made pursuant to a shelf registration statement filed January 9, 2029 and declared effective by the Securities and

Exchange Commission (the “SEC”) on January 22, 2026 (the “Registration Statement”) (File. No. 333-292665), a

base prospectus filed as part thereof, and a prospectus supplement dated May 21, 2026, filed pursuant to Rule 424(b)(5) under the Securities

Act.

The

foregoing summary of the terms of the Underwriting Agreement is subject to, and qualified in its entirety by reference to, the full text

of the Underwriting Agreement that is filed as Exhibit 1.1 to this Current Report on Form 8-K (this “Current Report”) and

is incorporated herein by reference. A copy of the opinion of Blank Rome LLP relating to the validity of the Shares in connection with

the Offering, is filed as Exhibit 5.1 to this Current Report.

This

Current Report shall not constitute an offer to sell, or the solicitation of an offer to buy, the securities discussed herein, nor shall

there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to

registration or qualification under the securities laws of any such state or jurisdiction.

May 21, 2026, the Company issued a press release announcing the pricing of the Offering, a copy of which is attached as Exhibit 99.1

to this Current Report.

Cautionary

Note Regarding Forward-Looking Statements

This

Current Report contains “forward-looking” statements within the meaning of the Securities Act, the Securities Exchange Act

of 1934, as amended, and of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including,

but not limited to statements regarding the expected net proceeds of the Offering, the anticipated use of the net proceeds of the Offering,

satisfaction of the closing conditions of the Offering and timing of the closing of the Offering. All statements other than statements

of historical fact are statements that could be deemed forward-looking statements. The words “believes,” “anticipates,”

“estimates,” “plans,” “expects,” “intends,” “may,” “could,” “should,”

“potential,” “likely,” “projects,” “continue,” “will,” “schedule,”

and “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking

statements contain these identifying words. These forward-looking statements are predictions based on the Company’s current expectations

and projections about future events and various assumptions, including the Company’s

cash runway and the satisfaction of customary closing conditions

related to the Offering. Forward-looking statements are subject to risks and uncertainties that may cause the Company’s actual

activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties

described under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December

31, 2025 and other documents that the Company files from time to time with the SEC. The forward-looking statements in this Current Report

speak only as of the date hereof, the Company undertakes no obligation to revise or update any forward-looking statements to reflect

events or circumstances after the date hereof, except as may be required by law.

Item

9.01 Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit

No.

Description

1.1

Underwriting Agreement, dated May 21, 2026, by and between Immix Biopharma, Inc. and Morgan Stanley & Co. LLC, as representative of the several underwriters.

5.1

Opinion of Blank Rome LLP.

23.1

Consent of Blank Rome LLP (included in Exhibit 5.1).

99.1

Press Release, dated May 21, 2026.

104

Cover

Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Immix

Biopharma, Inc.

Dated:

May 21, 2026

/s/

Ilya Rachman

Ilya

Rachman, Ph.D., M.D.

Chief

Executive Officer

EX-1.1

Filename: ex1-1.htm · Sequence: 2

Exhibit

1.1

IMMIX

BIOPHARMA, INC.

16,778,524

SHARES OF COMMON STOCK, PAR VALUE $0.0001 PER SHARE

UNDERWRITING

AGREEMENT

May

21, 2026

May

21, 2026

Morgan

Stanley & Co. LLC

c/o Morgan

Stanley & Co. LLC

1585 Broadway

New York, New York 10036

Ladies

and Gentlemen:

Immix

Biopharma Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named

in Schedule I

hereto

(the “Underwriters”), for whom Morgan Stanley & Co. LLC is acting as representative (the “Representative”),

16,778,524 shares of its common stock, par value $0.0001 per share (the “Shares”) at an exercise price of $0.01 per

share. The shares of common stock, par value $0.0001 per share, of the Company to be outstanding after giving effect to the sales contemplated

hereby are hereinafter referred to as the “Common Stock.”

The

Company has filed with the Securities and Exchange Commission (the “Commission”) a shelf registration statement on

Form S-3 (File No. 333-292665), including a prospectus relating to certain securities, including common stock, preferred stock, debt

securities, warrants and units, to be issued from time to time by the Company (the “Base Prospectus”). The registration

statement as amended at the time it became effective, including the information (if any) deemed to be part of the registration statement

at the time of effectiveness pursuant to Rule 430A under the Securities Act of 1933, as amended (the “Securities Act”),

is hereinafter referred to as the “Registration Statement”; the Base Prospectus and the final prospectus supplement

in the form first used to confirm sales of Shares (or in the form first made available to the Underwriters by the Company to meet requests

of purchasers pursuant to Rule 173 under the Securities Act) is hereinafter referred to as the “Prospectus.” If the

Company has filed an abbreviated registration statement to register additional shares of Common Stock pursuant to Rule 462(b) under the

Securities Act (a “Rule 462 Registration Statement”), then any reference herein to the term “Registration

Statement” shall be deemed to include such Rule 462 Registration Statement.

For

purposes of this Agreement, “free writing prospectus” has the meaning set forth in Rule 405 under the Securities Act,

“preliminary prospectus” shall mean the Base Prospectus that omitted information pursuant to Rule 430A under the Securities

Act that was used after such effectiveness and prior to the execution and delivery of this Agreement, “Time of Sale Prospectus”

means the preliminary prospectus together with the documents and pricing information set forth in Schedule II hereto, and “broadly

available road show” means a “bona fide electronic road show” as defined in Rule 433(h)(5) under the Securities

Act that has been made available without restriction to any person. As used herein, the terms “Registration Statement,” “preliminary

prospectus,” “Time of Sale Prospectus” and “Prospectus” shall include the documents, if any, incorporated

by reference therein as of the date hereof. The terms “supplement,” “amendment” and “amend”

as used herein with respect to the Registration Statement, the Prospectus, the Time of Sale Prospectus or the Prospectus shall include

all documents subsequently filed by the Company with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the

“Exchange Act”), that are deemed to be incorporated by reference therein.

Representations and Warranties. The Company represents and warrants to and agrees with each of the Underwriters that:

(a)

The Registration Statement has become effective; no stop order suspending the effectiveness of the Registration Statement is in effect,

and no proceedings for such purpose or pursuant to Section 8A under the Securities Act are pending before or, to the Company’s

knowledge, threatened by the Commission.

(b)

(i) Each document, if any, filed, or to be filed pursuant to the Exchange Act and incorporated by reference in the Time of Sale Prospectus

or the Prospectus complied (at the time of filing, or to the extent amended prior to the date hereof, on the date amended) or will comply

when so filed in all material respects with the Exchange Act and the applicable rules and regulations of the Commission thereunder, (ii)

the Registration Statement, when it became effective, did not contain and, as amended or supplemented, if applicable, will not, as of

the date of such amendment or supplement, contain any untrue statement of a material fact or omit to state a material fact required to

be stated therein or necessary to make the statements therein not misleading, (iii) the Registration Statement and the Prospectus comply

and, as amended or supplemented, if applicable, as of the date of such amendment or supplement, will comply in all material respects

with the Securities Act and the applicable rules and regulations of the Commission thereunder, (iv) the Time of Sale Prospectus does

not, and at the time of each sale of the Shares in connection with the offering when the Prospectus is not yet available to prospective

purchasers and at the Closing Date (as defined in Section 4), the Time of Sale Prospectus, as then amended or supplemented by the Company,

if applicable, as of the date of such amendment or supplement, will not, contain any untrue statement of a material fact or omit to state

a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading,

(v) each broadly available road show, if any, when considered together with the Time of Sale Prospectus, does not contain any untrue

statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances

under which they were made, not misleading and (vi) the Prospectus, as of its date, does not contain and, as amended or supplemented,

if applicable, as of the date of such amendment or supplement, will not contain, as of the date of such amendment or supplement or as

of the Closing Date, any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein,

in the light of the circumstances under which they were made, not misleading, except that the representations and warranties set forth

in this paragraph do not apply to statements or omissions in the Registration Statement, the Time of Sale Prospectus or the Prospectus

based upon information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representative

expressly for use therein, it being understood and agreed that the only such information furnished in writing by the Underwriters through

the Representative consists of the Underwriter Information (as defined below). Each document filed pursuant to the Exchange Act and incorporated

by reference in the Time of Sale Prospectus or the Prospectus complied when so filed, or to the extent it has been amended prior to the

date hereof, as of the date amended, in all material respects with the Exchange Act and the applicable rules and regulations of the Commission

thereunder.

(c)

The Company is not an “ineligible issuer” in connection with the offering pursuant to Rules 164, 405 and 433 under the Securities

Act. Any free writing prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will

be, filed with the Commission in accordance with the requirements of the Securities Act and the applicable rules and regulations of the

Commission thereunder. Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under

the Securities Act or that was prepared by or on behalf of or used or referred to by the Company complies or, if filed after the date

of this Agreement, will comply as of the date of such filing, in all material respects with the requirements of the Securities Act and

the applicable rules and regulations of the Commission thereunder. Except for the free writing prospectuses, if any, identified in Schedule

II hereto, and electronic road shows, if any, each furnished to the Representative before first use, the Company has not prepared,

used or referred to, and will not, without the prior consent of the Representative, prepare, use or refer to, any free writing prospectus.

(d)

The Company has been duly incorporated, is validly existing as a corporation in good standing under the laws of the jurisdiction of its

incorporation, has the corporate power and authority to own or lease its property and to conduct its business as described in each of

the Registration Statement, the Time of Sale Prospectus and the Prospectus and is duly qualified to transact business and is in good

standing in each jurisdiction (to the extent the concept of good standing or an equivalent concept is applicable in such jurisdiction)

in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the

failure to be so qualified or be in good standing would not, individually or in the aggregate, reasonably be expected to have a material

adverse effect on the Company and its subsidiaries, taken as a whole.

(e)

Each “significant subsidiary” (as such term is defined in Rule 1-02(w) of Regulation S-X) of the Company has been duly incorporated,

organized or formed, is validly existing as a corporation or other business entity in good standing under the laws of the jurisdiction

of its incorporation, organization or formation (to the extent the concept of good standing or any functional equivalent is applicable

in such jurisdiction), has the corporate or other business entity power and authority to own or lease its property and to conduct its

business as described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus and is duly qualified to

transact business and is in good standing in each jurisdiction (to the extent the concept of good standing or any functional equivalent

is applicable in such jurisdiction) in which the conduct of its business or its ownership or leasing of property requires such qualification,

except to the extent that the failure to be so qualified or be in good standing would not, individually or in the aggregate, reasonably

be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole; all of the issued shares of capital

stock or other equity interests of each significant subsidiary have been duly and validly authorized and issued, are fully paid and non-assessable

and are owned directly by the Company, free and clear of all liens, encumbrances, equities or claims, except for such liens, encumbrances,

equities or claims that would not, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company

and its subsidiaries, taken as a whole.

(f)

This Agreement has been duly authorized, executed and delivered by the Company.

(g)

The authorized capital stock of the Company conforms in all material respects as to legal matters to the description thereof contained

in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus as of the dates set forth therein.

(h)

The shares of Common Stock outstanding prior to the issuance of the Shares have been duly authorized and are validly issued, fully paid

and non-assessable.

(i)

The Shares have been duly authorized and, when issued, delivered and paid for in accordance with the terms of this Agreement, will be

validly issued, fully paid and non-assessable, and the issuance of the Shares will not be subject to any preemptive or similar rights.

(j)

The execution and delivery by the Company of, and the performance by the Company of its obligations under, this Agreement will not contravene

any provision of applicable law or the certificate of incorporation or by-laws of the Company or any agreement or other instrument binding

upon the Company or any of its significant subsidiaries that is material to the Company and its significant subsidiaries, taken as a

whole, or any judgment, order or decree of any governmental body, agency or court having jurisdiction over the Company or any significant

subsidiary, and no consent, approval, authorization or order of, or qualification with, any governmental body, agency or court is required

for the performance by the Company of its obligations under this Agreement, except such as may be required by the securities or Blue

Sky laws of the various states in connection with the offer and sale of the Shares.

(k)

There has not occurred any material adverse change, or any development involving a prospective material adverse change, in the condition,

financial or otherwise, or in the earnings, business or operations of the Company and its subsidiaries, taken as a whole, from that set

forth in the Time of Sale Prospectus.

(l)

There are no legal or governmental proceedings pending or, to the knowledge of the Company, threatened to which the Company or any of

its subsidiaries is a party or to which any of the properties of the Company or any of its subsidiaries is subject (i) other than proceedings

accurately described in all material respects in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus and

proceedings that would not, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its

subsidiaries, taken as a whole, or on the power or ability of the Company to perform its obligations under this Agreement or to consummate

the transactions contemplated by each of the Registration Statement, the Time of Sale Prospectus and the Prospectus or (ii) that are

required to be described in the Registration Statement, the Time of Sale Prospectus or the Prospectus and are not so described in all

material respects; and there are no statutes, regulations, contracts or other documents that are required to be described in the Registration

Statement, the Time of Sale Prospectus or the Prospectus or to be filed as exhibits to the Registration Statement that are not described

in all material respects or filed as required.

(m)

Each preliminary prospectus filed as part of the Registration Statement as originally filed or as part of any amendment thereto, or filed

pursuant to Rule 424 under the Securities Act, complied when so filed in all material respects with the Securities Act and the applicable

rules and regulations of the Commission thereunder.

(n)

The Company is not, and after giving effect to the offering and sale of the Shares and the application of the proceeds thereof as described

in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus will not be, required to register as an “investment

company” as such term is defined in the Investment Company Act of 1940, as amended.

(o)

No material labor dispute with the employees of the Company or any of its subsidiaries exists or, to the knowledge of the Company, is

imminent; and the Company is not aware of any existing, threatened or imminent labor disturbance by the employees of any of its principal

suppliers, manufacturers or contractors that would reasonably be expected have a material adverse effect on the Company and its subsidiaries,

taken as a whole.

(p)

The Company and each of its subsidiaries, taken as a whole, (i) are in compliance with any and all applicable foreign, federal, state

and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances

or wastes, pollutants or contaminants (“Environmental Laws”), (ii) have received all permits, licenses or other approvals

required of them under applicable Environmental Laws to conduct their respective businesses and (iii) are in compliance with all terms

and conditions of any such permit, license or approval, except where such noncompliance with Environmental Laws, failure to receive required

permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would

not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries,

taken as a whole.

(q)

There are no costs or liabilities associated with Environmental Laws (including, without limitation, any capital or operating expenditures

required for clean-up, closure of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints

on operating activities and any potential liabilities to third parties) which would, individually or in the aggregate, reasonably be

expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole.

(r)

Except as have been waived or complied with or as otherwise described in the Time of Sale Prospectus or the Prospectus, there are no

contracts, agreements or understandings between the Company and any person granting such person the right to require the Company to file

a registration statement under the Securities Act with respect to any securities of the Company or to require the Company to include

such securities with the Shares registered pursuant to the Registration Statement.

(s)

(i) None of the Company or any of its subsidiaries or affiliates, or any director, officer, or employee of the Company nor, to the Company’s

knowledge, any agent or representative of the Company or of any of its subsidiaries or affiliates, has taken or will take any action

in furtherance of an offer, payment, promise to pay, or authorization or approval of the payment, giving or receipt of money, property,

gifts or anything else of value, directly or indirectly, to any government official (including any officer or employee of a government

or government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for

or on behalf of any of the foregoing, or any political party or party official or candidate for political office) in order to influence

official action, or to any person in violation of any applicable Anti-Corruption Laws (as defined below); (ii) the Company and each of

its subsidiaries and affiliates have conducted their businesses in compliance with all applicable Anti-Corruption Laws and have instituted

and maintained and will continue to maintain policies and procedures reasonably designed to promote and achieve compliance with such

laws and with the representations and warranties contained herein; and (iii) neither the Company nor any of its subsidiaries will use,

directly or indirectly, the proceeds of the offering in furtherance of an offer, payment, promise to pay, or authorization of the payment

or giving of money, or anything else of value, to any person in violation of any applicable Anti-Corruption Laws.

(t)

Neither the Company nor any of its subsidiaries or affiliates, nor any director, officer, or employee thereof, nor, to the Company’s

knowledge, any agent or representative of the Company or of any of its subsidiaries or affiliates, has taken or will take any action

in furtherance of an offer, payment, promise to pay, or authorization or approval of the payment, giving or receipt of money, property,

gifts or anything else of value, directly or indirectly, to any person to improperly influence official action by that person for the

benefit of the Company or its subsidiaries or affiliates, or to otherwise secure any improper advantage, or to any person in violation

of (a) the U.S. Foreign Corrupt Practices Act of 1977, (b) the UK Bribery Act 2010, or (c) any other applicable law, regulation, order,

decree or directive having the force of law and relating to bribery or corruption (collectively, the “Anti-Corruption Laws”).

(u)

The operations of the Company and each of its subsidiaries are and have been conducted at all times in compliance with all applicable

anti-money laundering laws, rules, and regulations, including the financial recordkeeping and reporting requirements contained therein,

and including the Bank Secrecy Act of 1970, applicable provisions of the USA PATRIOT Act of 2001, the Money Laundering Control Act of

1986, and the Anti-Money Laundering Act of 2020 (collectively, the “Anti-Money Laundering Laws”).

(v)

(i) Neither the Company nor any of its subsidiaries, nor any director, officer, employee thereof, or, to the Company’s knowledge,

any, agent, affiliate, or representative of the Company or any of its subsidiaries, is an individual or entity (“Person”)

that is, or is owned or controlled by one or more Persons that are:

(A) the

subject of any sanctions administered or enforced by the United States Government (including

the U.S. Department of the Treasury’s Office of Foreign Assets Control and the U.S.

Department of State), the United Nations Security Council, the European Union, His Majesty’s

Treasury, or any other relevant sanctions authority (collectively, “Sanctions”),

(B) located,

organized or resident in a country or territory that is the subject of comprehensive territorial

Sanctions (including, without limitation, the so-called Donetsk People’s Republic,

the so-called Luhansk People’s Republic, or any other Covered Region of Ukraine identified

pursuant to Executive Order 14065, Crimea, Cuba, Iran, and North Korea).

(ii)

The Company and each of its subsidiaries (a) have not, since April 24, 2019, engaged in, (b) are not now engaged in, and (c) will not

engage in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction

is or was, or whose government is or was, the subject of Sanctions.

(w)

The Company will not, directly or indirectly, use the proceeds of the offering, or lend, contribute or otherwise make available such

proceeds to any subsidiary, joint venture partner or other Person:

(i)

to fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding

or facilitation, is, or whose government is, the subject of Sanctions;

(ii)

to fund or facilitate any money laundering or terrorist financing activities; or

(iii)

in any other manner that would cause or result in a violation of any Anti-Corruption Laws, Anti-Money Laundering Laws, or Sanctions by

any Person (including any Person participating in the offering, whether as underwriter, advisor, investor or otherwise).

(x)

The Company and its subsidiaries have conducted and will conduct their businesses in compliance with the Anti-Corruption Laws, the Anti-Money

Laundering Laws, and Sanctions, and no investigation, inquiry, action, suit or proceeding by or before any court or governmental agency,

authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Corruption Laws, the Anti-Money

Laundering Laws, or Sanctions is pending or, to the knowledge of the Company, threatened. The Company and its subsidiaries and affiliates

have instituted and maintained and will continue to maintain policies and procedures reasonably designed to promote and achieve compliance

with the Anti-Corruption Laws, the Anti-Money Laundering Laws, Sanctions, and with the representations and warranties contained herein.

(y)

(i) The Company and its subsidiaries own or have a valid license to use any and all patents, inventions, copyrights, copyrightable works,

licenses, know how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems

or procedures), software, domain names, trademarks, service marks, trade names and other source indicators and all other worldwide intellectual

property and proprietary rights (including all registrations and applications for registration of, and all goodwill associated with,

any of the foregoing) (collectively, “Intellectual Property Rights”) used in, held for use in or reasonably necessary

to the conduct of their respective businesses as now conducted by them, and as proposed to be conducted in the Registration Statement,

the Time of Sale Prospectus and the Prospectus; (ii) the Intellectual Property Rights owned and exclusively licensed by the Company and

its subsidiaries are, to the Company’s knowledge, valid, subsisting and enforceable, and there is no pending or, to the Company’s

knowledge, threatened action, suit, proceeding or claim by others challenging the validity, scope or enforceability of, or any rights

of the Company or any of its subsidiaries in, any such Intellectual Property Rights; (iii) neither the Company nor any of its subsidiaries

has received any notice or other threat alleging, or is a party to any action, suit, investigation or proceeding involving any allegation

of, any infringement, misappropriation or other violation of any Intellectual Property Rights; (iv) to the Company’s knowledge,

no third party is infringing, misappropriating or otherwise violating, or has infringed, misappropriated or otherwise violated, any Intellectual

Property Rights owned or exclusively licensed by the Company or any of its subsidiaries; (v) to the Company’s knowledge, neither

the Company nor any of its subsidiaries, nor the conduct of their respective businesses, infringes, misappropriates or otherwise violates,

or has infringed, misappropriated or otherwise violated, any Intellectual Property Rights; (vi) all employees and contractors engaged

in the development of Intellectual Property Rights on behalf of the Company or any subsidiary of the Company have executed an invention

assignment agreement whereby such employees and contractors presently assign all of their right, title and interest in and to such Intellectual

Property Rights to the Company or its applicable subsidiary, and to the Company’s knowledge no such agreement has been breached

or violated; and (vii) the Company and its subsidiaries use, and have used, commercially reasonable efforts to appropriately maintain

the confidentiality of all trade secrets and other confidential information of the Company and its subsidiaries, and no such trade secrets

or other confidential information have been disclosed other than to employees, representatives and agents of the Company or any of its

subsidiaries, all of whom are bound by written confidentiality agreements.

(z)

Except as would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its

subsidiaries, taken as a whole, (i) the Company and each of its subsidiaries have complied and are presently in compliance with all internal

and external privacy policies and notices, contractual obligations, industry standards, applicable laws, statutes, judgments, orders,

rules and regulations of any court or arbitrator or other governmental or regulatory authority and any other legal obligations, in each

case, relating to the collection, use, transfer, import, export, storage, protection, disposal, disclosure and other processing by the

Company or any of its subsidiaries of personal, personally identifiable, household, sensitive, confidential or regulated data or information

(“Data Security Obligations”, and such data and information, “Personal Data”); (ii) the Company

and its subsidiaries have not received any written notification of or written complaint regarding and are unaware of any other facts

that, individually or in the aggregate, would reasonably indicate non-compliance with any Data Security Obligation by the Company or

any of its subsidiaries; and (iii) there is no action, suit, investigation or proceeding by or before any court or governmental agency,

authority or body pending or, to the Company’s knowledge, threatened, against the Company or any of its subsidiaries alleging non-compliance

with any Data Security Obligation by the Company or any of its subsidiaries.

(aa)

Except as would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its

subsidiaries, taken as a whole, the Company’s and its subsidiaries’ respective information technology assets and equipment,

computers, systems, networks, hardware, software, websites, applications, technology, data and databases (including Personal Data and

the data and information of their respective customers, employees, suppliers, vendors and any third-party data maintained, stored or

otherwise processed by or on behalf of the Company and its subsidiaries) used in connection with the operation of the Company’s

and its subsidiaries’ respective businesses (“IT Systems and Data”) are adequate for, and operate and perform

in all material respects as required in connection with, the operation of the business of the Company and its subsidiaries as currently

conducted, and, to the Company’s knowledge, the IT Systems and Data are free and clear of all bugs, errors, defects, Trojan horses,

time bombs, malware and other corruptants. The Company and each of its subsidiaries have taken all technical, physical, administrative

and organizational measures necessary to protect the IT Systems and Data, and without limiting the foregoing, the Company and its subsidiaries

have used reasonable efforts to establish and maintain, and have established, maintained, implemented and complied with, all reasonable

information technology, information security, cybersecurity and data protection controls, policies and procedures, including oversight,

access controls, encryption, technological and physical safeguards and business continuity/disaster recovery and security plans, consistent

with industry standards and practices, that are designed to protect against and prevent breach, destruction, loss, unauthorized distribution,

use, access, disablement, misappropriation or modification, or other compromise or misuse of or relating to any IT Systems and Data (“Breach”).

There has been no such Breach, and the Company and its subsidiaries have not been notified of and have no knowledge of any event or condition

that would reasonably be expected to result in, any such Breach.

(bb)

The Company and its subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state or foreign

regulatory authorities necessary to conduct their respective businesses, and neither the Company nor any of its subsidiaries has received

any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit which, singly or

in the aggregate, if the subject of an unfavorable decision, ruling or finding, would have a material adverse effect on the Company and

its subsidiaries, taken as a whole, except as described in the Registration Statement, the Time of Sale Prospectus and Prospectus.

(cc)

The Company and its subsidiaries have operated at all times and are currently in compliance with all applicable statutes, rules, regulations

and policies of the U.S. Food and Drug Administration (the “FDA”) and applicable foreign regulatory authorities, including

the European Medicines Agency and the UK Medicines & Healthcare products Regulatory Agency (collectively, the “Regulatory

Authorities”), except where failure to be in compliance would not reasonably be expected to have a material adverse effect

on the Company and its subsidiaries, taken as a whole, including, without limitation the following, as applicable: (i) the Federal Food,

Drug, and Cosmetic Act and the regulations promulgated thereunder; (ii) all applicable federal, state, local and foreign health care

laws, including, without limitation, the U.S. Anti-Kickback Statute (42 U.S.C. Section 1320a-7b(b)), the Civil Monetary Penalties Law

(42 U.S.C. § 1320a-7a), the U.S. Civil False Claims Act (31 U.S.C. Section 3729 et seq.), all applicable federal, state, local and

all foreign criminal laws relating to health care fraud and abuse, including but not limited to the U.S. False Statements Law (42 U.S.C.

Section 1320a-7b(a)), 18 U.S.C. Sections 286 and 287, and the health care fraud criminal provisions under the U.S. Health Insurance Portability

and Accountability Act of 1996 (“HIPAA”) (42 U.S.C. Section 1320d et seq.), the exclusion laws, the statutes, regulations

and directives of applicable government funded or sponsored healthcare programs, and the regulations promulgated pursuant to such statutes;

(iii) the Standards for Privacy of Individually Identifiable Health Information, the Security Standards, and the Standards for Electronic

Transactions and Code Sets promulgated under HIPAA, the Health Information Technology for Economic and Clinical Health Act (42 U.S.C.

Section 17921 et seq.), and the regulations promulgated thereunder and any state or non-U.S. counterpart thereof or any other law or

regulation the purpose of which is to protect the privacy of individuals or prescribers; (iv) the Patient Protection and Affordable Care

Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, the regulations promulgated thereunder; (v) the

U.S. Controlled Substances Act (21 U.S.C. Section 801 et seq.); (vi) the Clinical Laboratories Improvement Act of 1967, as amended);

(vii) licensure, quality, safety and accreditation requirements under applicable federal, state, local or foreign laws or regulatory

bodies; and (viii) all other local, state, federal, national, supranational and foreign laws, relating to the regulation of the Company

or its subsidiaries and the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling,

promotion, sale, offer for sale, storage, import, export or disposal of any product under development, manufactured or distributed by

the Company (clauses (i) through (vii), collectively, “Health Care Laws”).

(dd)

(i) The studies, tests and preclinical and clinical trials conducted by the Company, to the knowledge of the Company, any studies, tests

and preclinical and clinical trials conducted on behalf of or sponsored by the Company or its subsidiaries or in which the Company or

its subsidiaries have participated, were conducted and are being conducted in accordance with (A) standard medical and experimental protocols,

procedures and controls pursuant to accepted professional scientific research standards and procedures and (B) all applicable Health

Care Laws, rules and regulations of the Regulatory Authorities and current Good Clinical Practices and Good Laboratory Practices; (ii)

the descriptions of the results of such studies and trials contained in the Registration Statement, the Time of Sale Prospectus and the

Prospectus are accurate and complete in all material respects and fairly present the data derived from such trials and studies; (iii)

the Company has no knowledge of any other studies or trials not described in the Registration Statement, the Time of Sale Prospectus

and the Prospectus, the results of which the Company reasonably believes are inconsistent with or call into question the results described

or referred to in the Registration Statement, the Time of Sale Prospectus and the Prospectus; (iv)

the Company has provided the Representative with all material substantive written notices, correspondence and summaries of all other

material communications provided to the Company or its subsidiaries from the Regulatory Authorities; and (v)

neither the Company nor any of its subsidiaries have received any written notices, correspondence or other communications from any Regulatory

Authority or any other governmental entity requiring or threatening the termination, modification or suspension of any studies or trials

that are described in the Registration Statement, the Time of Sale Prospectus and the Prospectus or the results of which are referred

to in the Registration Statement, the Time of Sale Prospectus and the Prospectus, and, to the Company’s knowledge, there are no

reasonable grounds for the same.

(ee)

(i) The Company and its subsidiaries have filed, obtained, maintained

or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments

as required by any applicable Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions

and supplements or amendments were, in all material respects, timely, complete, accurate and not misleading on the date filed (or were

corrected or supplemented by a subsequent submission); (ii) neither the

Company nor its subsidiaries have received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation,

arbitration or other action from any court or arbitrator or Regulatory Authority, other governmental entity or third party alleging that

any Company, subsidiary, or product operation or activity is in violation of any Health Care Laws, including, without limitation, any

FDA Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence or notice from the FDA or any other

Regulatory Authority or governmental entity, nor, to the Company’s knowledge, is any such claim, action, suit, proceeding, hearing,

enforcement, investigation, arbitration or other action threatened or under consideration by the FDA or any other Regulatory Authority;

(iii) neither the Company nor its subsidiaries are a party to any corporate

integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any Regulatory

Authority or other governmental entity; and (iv) neither the Company,

its subsidiaries nor any of their respective employees, officers or directors has been excluded, suspended or debarred from participation

in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is subject to an inquiry, investigation,

proceeding or other similar action by a Regulatory Authority or other governmental entity that could reasonably be expected to result

in debarment, suspension, or exclusion.

(ff)

The Company and each of its subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks

and in such amounts as, in the reasonable judgment of the Company, are prudent and customary in the businesses in which they are engaged;

neither the Company nor any of its subsidiaries has been refused any insurance coverage sought or applied for; and neither the Company

nor any of its subsidiaries has any reason to believe that it will not be able to renew its existing insurance coverage as and when such

coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would

not, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken

as a whole.

(gg)

The Company and each of its subsidiaries have filed all federal, state, local and foreign tax returns required to be filed through the

date of this Agreement or have requested extensions thereof (except where the failure to file would not, singly or in the aggregate,

have a material adverse effect on the Company and its subsidiaries, taken as a whole) and have paid all taxes required to be paid thereon

(except for cases in which the failure to file or pay would not, singly or in the aggregate, have a material adverse effect on the Company

and its subsidiaries, taken as a whole, or, except as currently being contested in good faith and for which reserves required by generally

accepted accounting principles (“U.S. GAAP”) have been created in the financial statements of the Company), and no

tax deficiency has been determined adversely to the Company or any of its subsidiaries which, singly or in the aggregate, has had (nor

does the Company nor any of its subsidiaries have any notice or knowledge of any tax deficiency which could reasonably be expected to

be determined adversely to the Company or its subsidiaries and which could reasonably be expected to have) a material adverse effect

on the Company and its subsidiaries, taken as a whole.

(hh)

The financial statements included or incorporated by reference in each of the Registration Statement, the Time of Sale Prospectus and

the Prospectus, together with the related schedules and notes thereto, comply as to form in all material respects with the applicable

accounting requirements of the Securities Act and present fairly in all material respects the consolidated financial position of the

Company and its consolidated subsidiaries as of the dates shown and its results of operations and cash flows for the periods shown, and

such financial statements have been prepared in conformity with U.S. GAAP applied on a consistent basis throughout the periods covered

thereby except for any normal year-end adjustments in the Company’s quarterly financial statements. The other financial information

of the Company and its consolidated subsidiaries included in each of the Registration Statement, the Time of Sale Prospectus and the

Prospectus has been derived from the accounting records of the Company and its consolidated subsidiaries and presents fairly in all material

respects the information shown thereby. The statistical, industry-related and market-related data included in each of the Registration

Statement, the Time of Sale Prospectus and the Prospectus are based on or derived from sources which the Company reasonably and in good

faith believes are reliable and accurate and such data is consistent with the sources from which they are derived, in each case in all

material respects and, to the extent required, the Company has obtained the written consent to the use of such data from such sources.

(ii)

Crowe LLP, who has certified certain financial statements of the Company and its subsidiaries and delivered its report with respect to

the audited consolidated financial statements and schedules filed with the Commission as part of the Registration Statement and included

in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, is an independent registered public accounting

firm with respect to the Company within the meaning of the Securities Act and the applicable rules and regulations thereunder adopted

by the Commission and the Public Company Accounting Oversight Board (United States).

(jj)

The Company and each of its subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance

that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded

as necessary to permit preparation of financial statements in conformity with U.S. GAAP and to maintain asset accountability; (iii) access

to assets is permitted only in accordance with management’s general or specific authorization; (iv) the recorded accountability

for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences;

and (v) the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement

is accurate. Since the end of the Company’s most recent audited fiscal year, except as described in the Registration Statement,

the Time of Sale Prospectus and the Prospectus, there has been (i) no material weakness in the Company’s internal control over

financial reporting (whether or not remediated) and (ii) no change in the Company’s internal control over financial reporting that

has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

(kk)

The Company maintains a system of disclosure controls and procedures (as such term is defined in Rule 13a-15(e) under the Exchange Act)

that are designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange

Act is recorded, processed, summarized and reported within the time periods specified in the Commission’s rules and forms, including

controls and procedures designed to ensure that such information is accumulated and communicated to the Company’s management as

appropriate to allow timely decisions regarding required disclosure. The Company has carried out evaluations of the effectiveness of

its disclosure controls and procedures as required by Rule 13a-15 of the Exchange Act and such disclosure controls and procedures were

effective at the reasonable assurance level as of the end of the Company’s most recently completed fiscal quarter, except as described

in the Registration Statement, the Time of Sale Prospectus and the Prospectus.

(ll)

The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly

presents the information called for in all material respects and has been prepared in accordance with the Commission’s rules and

guidelines applicable thereto.

(mm)

From the time of the submission of the Registration Statement to the Commission through the date hereof, the Company has been and is

an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).

(nn)

The Company (i) has not alone engaged in any Testing-the-Waters Communication with any person and (ii) has not authorized anyone other

than the Representative to engage in Testing-the-Waters Communications. The Company reconfirms that the Representative has been authorized

to act on its behalf in undertaking Testing-the-Waters Communications. The Company has not distributed any Testing-the-Waters Communication

that is a written communication within the meaning of Rule 405 under the Securities Act. “Testing-the-Waters Communication”

means any communication with potential investors undertaken in reliance on Section 5(d) or Rule 163B of the Securities Act.

(oo)

As of the time of each sale of the Shares in connection with the offering when the Prospectus is not yet available to prospective purchasers,

none of (A) the Time of Sale Prospectus, (B) any free writing prospectus, when considered together with the Time of Sale Prospectus,

and (C) any individual Testing-the-Waters Communication, when considered together with the Time of Sale Prospectus, included, includes

or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to

make the statements therein, in the light of the circumstances under which they were made, not misleading.

(pp)

Neither the Company nor any of its subsidiaries has any securities rated by any “nationally recognized statistical rating organization,”

as such term is defined in Section 3(a)(62) of the Exchange Act.

(qq)

Neither the Company nor any of its subsidiaries is or shall become a “covered foreign person,” as that term is used in the

regulations administered and enforced by the U.S. Treasury Department under U.S. Executive Order 14105 and codified at 31 C.F.R. §

850.101 et seq. (the “Outbound Investment Rules”). Neither the Company nor any of its subsidiaries currently engages,

directly or indirectly, in (i) a “covered activity” or a “covered transaction,” as each such term is defined

in the Outbound Investment Rules, (ii) any activity or transaction that would constitute a “covered activity” or a “covered

transaction,” as each such term is defined in the Outbound Investment Rules, if the Company were a “U.S. Person” (as

defined below), or (iii) any other activity that would cause any Underwriter or any of its affiliates to be in violation of the Outbound

Investment Rules or cause any Underwriter or any of its affiliates to be legally prohibited by the Outbound Investment Rules from performing

under this Agreement. For purposes of this paragraph, a “U.S. Person” means any United States citizen, lawful permanent

resident, entity organized under the laws of the United States or any jurisdiction within the United States, including any foreign branch

of any such entity, or any person in the United States.

2. Agreements

to Sell and Purchase. The Company hereby agrees to sell to the several Underwriters, and each Underwriter, upon the basis of the

representations and warranties herein contained, but subject to the terms and conditions hereinafter stated, agrees, severally and

not jointly, to purchase from the Company the respective number of Shares set forth in Schedule I hereto opposite its

name at $8.4036 a share (the “Share Purchase Price”).

Terms of Public Offering. The Company is advised by the Representative that the Underwriters propose to make a public offering

of their respective portions of the Shares as soon after the Registration Statement and this Agreement have become effective as in the

Representative’s judgment is advisable. The Company is further advised by Morgan Stanley that the Shares are to be offered to the

public initially at $8.94 a share (the “Public Offering Price”) and to certain dealers selected by the Representative

at a price that represents a concession not in excess of $0.32184 a share under the Public Offering Price.

Payment and Delivery. Payment for the Shares shall be made to the Company in Federal or other funds immediately available in New

York City against delivery of such Shares for the respective accounts of the several Underwriters at 10:00 a.m., New York City time,

on May 22, 2026, or at such other time on the same or such other date, not later than May 29, 2026, as shall be designated in writing

by the Representative. The time and date of such payment are hereinafter referred to as the “Closing Date.”

The

Shares shall be registered in such names and in such denominations as the Representative shall request not later than one full business

day prior to the Closing Date. The Shares shall be delivered to the Representative on the Closing Date for the respective accounts of

the several Underwriters, with any transfer taxes payable in connection with the transfer of the Shares to the Underwriters duly paid,

against payment of the Purchase Price therefor.

Conditions to the Underwriters’ Obligations. The obligations of the Company to sell the Shares to the Underwriters and the

several obligations of the Underwriters to purchase and pay for the Shares on the Closing Date are subject to the condition that the

Registration Statement shall remain effective as of the date hereof.

The

several obligations of the Underwriters are subject to the following further conditions:

(a)

Subsequent to the execution and delivery of this Agreement and prior to the Closing Date:

(i)

no order suspending the effectiveness of the Registration Statement shall be in effect, and no proceeding for such purpose or pursuant

to Section 8A under the Securities Act shall be pending before or, to the Company’s knowledge, threatened by the Commission; and

(ii)

there shall not have occurred any change, or any development involving a prospective change, in the condition, financial or otherwise,

or in the earnings, business or operations of the Company and its subsidiaries, taken as a whole, from that set forth in the Time of

Sale Prospectus that, in the judgment of the Representative, is material and adverse and that makes it, in the judgment of the Representative,

impracticable to market the Shares on the terms and in the manner contemplated in the Time of Sale Prospectus.

(b)

The Underwriters shall have received on the Closing Date a certificate, dated the Closing Date and signed by an executive officer of

the Company, to the effect set forth in Sections 5(a)(i) and 5(a)(ii) above and to the effect that the representations and warranties

of the Company contained in this Agreement are true and correct as of the Closing Date and that the Company has complied with all of

the agreements and satisfied all of the conditions on its part to be performed or satisfied hereunder on or before the Closing Date.

The officer signing and delivering such certificate may rely upon the best of his or her knowledge as to proceedings threatened.

(c)

The Underwriters shall have received on the Closing Date an opinion and negative assurance letter of Blank Rome, LLP, outside counsel

for the Company, dated the Closing Date, in form and substance reasonably satisfactory to the Representative.

(d)

The Underwriters shall have received on the Closing Date an opinion of Dickinson Wright LLP, outside intellectual property counsel for

the Company, dated the Closing Date, in form and substance reasonably satisfactory to the Representative.

(e)

The Underwriters shall have received on the Closing Date an opinion and negative assurance letter of Davis Polk & Wardwell LLP, counsel

for the Underwriters, dated the Closing Date, in form and substance reasonably satisfactory to the Representative.

With

respect to Section ‎5‎(c) above, Blank Rome, LLP may state that their opinions and beliefs are based upon their participation

in the preparation of the Time of Sale Prospectus and the Prospectus and any amendments or supplements thereto and review and discussion

of the contents thereof, but are without independent check or verification, except as specified. With respect to Section ‎5(e) above,

Davis Polk & Wardwell LLP may state that their opinions and beliefs are based upon their participation in the preparation of the

Time of Sale Prospectus and the Prospectus and any amendments or supplements thereto (other than the documents incorporated by reference)

and upon review and discussion of the contents thereof (including documents incorporated by reference), but are without independent check

or verification, except as specified.

(f)

The Underwriters shall have received, on each of the date hereof and the Closing Date, a letter dated the date hereof or the Closing

Date, as the case may be, in form and substance satisfactory to the Representative, from Crowe LLP, independent public accountants, containing

statements and information of the type ordinarily included in accountants’ “comfort letters” to underwriters with respect

to the financial statements and certain financial information contained in the Registration Statement, the Time of Sale Prospectus and

the Prospectus; provided that the letter delivered on the Closing Date shall use a “cut-off date” not earlier than

the date hereof.

(g)

The “lock-up” agreements, each substantially in the form of Exhibit A hereto, between the Representative and certain

officers and directors of the Company relating to restrictions on sales and certain other dispositions of shares of Common Stock or certain

other securities, delivered to the Representative on or before the date hereof, shall be in full force and effect on the Closing Date.

(h)

Such other documents as the Representative may reasonably request, including with respect to the good standing of the Company and its

subsidiaries, the due authorization and issuance of the Shares and other matters related to the issuance of the Shares.

Covenants of the Company. The Company covenants with each Underwriter as follows:

(a)

To furnish to the Representative, upon written request, without charge, two signed copies of the Registration Statement (including exhibits

thereto and documents incorporated by reference) and for delivery to each other Underwriter a conformed copy of the Registration Statement

(without exhibits thereto but including documents incorporated by reference) and to furnish to the Representative in New York City, without

charge, prior to 10:00 a.m. New York City time on the business day next succeeding the date of this Agreement and during the period mentioned

in Section 6(e) or 6(f) below, as many copies of the Time of Sale Prospectus, the Prospectus, any documents incorporated by reference

therein and any supplements and amendments thereto or to the Registration Statement as the Representative may reasonably request.

(b)

Prior to Closing, before amending or supplementing the Registration Statement, the Time of Sale Prospectus or the Prospectus, to furnish

to the Representative a copy of each such proposed amendment or supplement and not to file any such proposed amendment or supplement

to which the Representative reasonably objects, and to file with the Commission within the applicable period specified in Rule 424(b)

under the Securities Act any prospectus required to be filed pursuant to such Rule.

(c)

To furnish to the Representative a copy of each proposed free writing prospectus to be prepared by or on behalf of, used by, or referred

to by the Company and not to use or refer to any proposed free writing prospectus to which the Representative reasonably objects.

(d)

Not to take any action that would result in an Underwriter or the Company being required to file with the Commission pursuant to Rule

433(d) under the Securities Act a free writing prospectus prepared by or on behalf of the Underwriter that the Underwriter otherwise

would not have been required to file thereunder.

(e)

If the Time of Sale Prospectus is being used to solicit offers to buy the Shares at a time when the Prospectus is not yet available to

prospective purchasers and any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Time

of Sale Prospectus in order to make the statements therein, in the light of the circumstances, not misleading, or if any event shall

occur or condition exist as a result of which the Time of Sale Prospectus conflicts with the information contained in the Registration

Statement then on file, or if, in the reasonable opinion of counsel for the Underwriters, it is necessary to amend or supplement the

Time of Sale Prospectus to comply with applicable law, forthwith to prepare, file with the Commission and furnish, at its own expense,

to the Underwriters and to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so that the statements

in the Time of Sale Prospectus as so amended or supplemented will not, in the light of the circumstances when the Time of Sale Prospectus

is delivered to a prospective purchaser, be misleading or so that the Time of Sale Prospectus, as amended or supplemented, will no longer

conflict with the Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply with applicable

law.

(f)

If, during such period after the first date of the public offering of the Shares as in the reasonable opinion of counsel for the Underwriters

the Prospectus (or in lieu thereof the notice referred to in Rule 173(a) of the Securities Act) is required by law to be delivered in

connection with sales by an Underwriter or dealer, any event shall occur or condition exist as a result of which it is necessary to amend

or supplement the Prospectus in order to make the statements therein, in the light of the circumstances when the Prospectus (or in lieu

thereof the notice referred to in Rule 173(a) of the Securities Act) is delivered to a purchaser, not misleading, or if, in the reasonable

opinion of counsel for the Underwriters, it is necessary to amend or supplement the Prospectus to comply with applicable law, forthwith

to prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to the dealers (whose names and addresses

the Representative will furnish to the Company) to which Securities may have been sold by the Representative on behalf of the Underwriters

and to any other dealers upon request, either amendments or supplements to the Prospectus so that the statements in the Prospectus as

so amended or supplemented will not, in the light of the circumstances when the Prospectus (or in lieu thereof the notice referred to

in Rule 173(a) of the Securities Act) is delivered to a purchaser, be misleading or so that the Prospectus, as amended or supplemented,

will comply with applicable law.

(g)

To endeavor to qualify the Shares for offer and sale under the securities or Blue Sky laws of such jurisdictions as the Representative

shall reasonably request; provided, however, that nothing contained herein shall require the Company to qualify as a foreign corporation

or other entity or as a dealer in securities in any jurisdiction where it would not otherwise be required to so qualify or file any general

consent to service of process in any such jurisdiction or to subject itself to taxation in any such jurisdiction of it is not otherwise

so subject.

(h)

To make generally available to the Company’s securityholders and to the Representative as soon as practicable, which may be satisfied

by filing with the Commission’s Electronic Data Gathering Analysis and Retrieval System, an earnings statement covering a period

of at least twelve months beginning with the first fiscal quarter of the Company occurring after the date of this Agreement which shall

satisfy the provisions of Section 11(a) of the Securities Act and the rules and regulations of the Commission thereunder.

(i)

Whether or not the transactions contemplated in this Agreement are consummated or this Agreement is terminated, to pay or cause to

be paid all expenses incident to the performance of its obligations under this Agreement, including: (i) the fees, disbursements and

expenses of the Company’s counsel and the Company’s accountants in connection with the registration and delivery of the

Shares under the Securities Act and all other fees or expenses in connection with the preparation and filing of the Registration

Statement, any preliminary prospectus, the Time of Sale Prospectus, the Prospectus, any free writing prospectus prepared by or on

behalf of, used by, or referred to by the Company and amendments and supplements to any of the foregoing, including all printing

costs associated therewith, and the mailing and delivering of copies thereof to the Underwriters and dealers, in the quantities

hereinabove specified, (ii) all costs and expenses related to the transfer and delivery of the Shares to the Underwriters, including

any transfer or other taxes payable thereon, (iii) the cost of printing or producing any Blue Sky or Legal Investment memorandum in

connection with the offer and sale of the Shares under state securities laws and all expenses in connection with the qualification

of the Shares for offer and sale under state securities laws as provided in Section 6(g) hereof, including filing fees and the

reasonable fees and disbursements of counsel for the Underwriters in connection with such qualification and in connection with the

Blue Sky or Legal Investment memorandum, (iv) all filing fees and the reasonable fees and disbursements of counsel to the

Underwriters incurred in connection with the review and qualification of the offering of the Shares by the Financial Industry

Regulatory Authority, (v) all costs and expenses incident to listing the Shares on the Nasdaq Capital Market, (vi) the cost of

printing certificates representing the Securities, (vii) the costs and charges of any transfer agent, registrar or depositary,

(viii) the costs and expenses of the Company relating to investor presentations on any “road show” undertaken in

connection with the marketing of the offering of the Shares, including, without limitation, expenses associated with the preparation

or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and

expenses of any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel

and lodging expenses of the representatives and officers of the Company and any such consultants, (ix) the document production

charges and expenses associated with printing this Agreement and (x) all other costs and expenses incident to the performance of the

obligations of the Company hereunder for which provision is not otherwise made in this Section 6. It is understood, however, that

except as provided in this Section 6, Section 8 entitled “Indemnity and Contribution” and the last paragraph of Section

10 below, the Underwriters will pay all of their costs and expenses, including fees and disbursements of their counsel, stock

transfer taxes payable on resale of any of the Shares by them and any advertising expenses connected with any offers they may

make.

(j)

The Company will promptly notify the Representative if the Company ceases to be an Emerging Growth Company at any time prior to the later

of (i) completion of the distribution of the Shares within the meaning of the Securities Act and (ii) completion of the Restricted Period

(as defined in this Section 6).

(k)

If at any time following the distribution of any Testing-the-Waters Communication that is a written communication within the meaning

of Rule 405 under the Securities Act there occurred or occurs an event or development as a result of which such Testing-the-Waters Communication

included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order

to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will

promptly notify the Representative and will promptly amend or supplement, at its own expense, such Testing-the-Waters Communication to

eliminate or correct such untrue statement or omission.

(l)

The Company also covenants with each Underwriter that, without the prior written consent of the Representative on behalf of the Underwriters,

it will not, and will not publicly disclose an intention to, during the period ending 90 days after the date of the Prospectus (the “Restricted

Period”), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract

to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares

of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock, or (2) enter into any swap or other

arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether

any such transaction described in clause 1 or 2 above is to be settled by delivery of Common Stock or such other securities, in cash

or otherwise or (3) file any registration statement with the Commission relating to the offering of any shares of Common Stock or any

securities convertible into or exercisable or exchangeable for Common Stock. The restrictions contained in the preceding paragraph shall

not apply to (A) the Shares to be sold hereunder, (B) the issuance by the Company of shares of Common Stock upon the exercise (including

any net exercise) of an option or warrant or the conversion of a security outstanding on the date hereof and described in the Time of

Sale Prospectus, (C) the issuance by the Company of options, restricted stock units or restricted stock awards (including the Common

Stock issued upon the settlement or exercise thereof) to employees, officers, directors, advisors, or consultants of the Company pursuant

to employee benefit plans (including equity incentive plans) described in the Time of Sale Prospectus and the Prospectus, provided

that, prior to the issuance of any such options, restricted stock units or restricted stock awards, the Company shall cause each recipient

of such securities who is a director or executive officer of the Company to execute and deliver a lock-up agreement substantially in

the form of Exhibit A hereto, (D) the filing by the Company of registration statements on Form S-8 with respect to employee benefit

plans (including any employee benefit plans assumed pursuant to clause (F)), (E) the establishment of a trading plan pursuant to Rule

10b5-1 under the Exchange Act for the transfer of shares of Common Stock, provided that (1) such plan does not provide for the

transfer of Common Stock during the Restricted Period and (2) to the extent a public announcement or filing under the Exchange Act, if

any, is required of or voluntarily made by the Company regarding the establishment of such plan, such announcement or filing shall include

a statement to the effect that no transfer of Common Stock may be made under such plan during the Restricted Period), and (F) the issuance

by the Company of shares of Common Stock or securities convertible into, exchangeable for or that represent the right to receive Common

Stock in connection with (1) the acquisition by the Company or any of its subsidiaries of the securities, business, technology, property

or other assets of another person or entity or pursuant to an employee benefit plan assumed by the Company in connection with such acquisition,

(2) the Company’s joint ventures, equipment leasing arrangements, licensing transactions, collaborations and other strategic transactions;

provided that the aggregate number of shares of Common Stock that the Company may sell or issue or agree to sell or issue pursuant to

this clause (F) shall not exceed 5% of the total number of shares of Common Stock outstanding immediately following the completion of

the transactions contemplated by this Agreement and the Company shall cause each recipient of such securities to execute and deliver

to the Representative, on or prior to the issuance of such securities, a lock-up agreement on substantially the same terms as the lock-up

letter described in Section 5(h) hereof to the extent and for the duration that such terms remain in effect at the time of the transfer.

Covenants of the Underwriters. Each Underwriter, severally and not jointly, covenants with the Company not to take any action

that would result in the Company being required to file with the Commission under Rule 433(d) a free writing prospectus prepared by or

on behalf of such Underwriter that otherwise would not be required to be filed by the Company thereunder, but for the action of the Underwriter.

Indemnity and Contribution. (a) The Company agrees to indemnify and hold harmless each Underwriter, its affiliates, directors,

officers, employees and agents, and each person, if any, who controls any Underwriter within the meaning of either Section 15 of the

Securities Act or Section 20 of the Exchange Act and each affiliate of any Underwriter within the meaning of Rule 405 under the Securities

Act from and against any and all losses, claims, damages and liabilities (including, without limitation, any legal or other expenses

reasonably incurred in connection with defending or investigating any such action or claim) that arise out of, or are based upon, any

untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or any amendment thereof, any

preliminary prospectus, the Time of Sale Prospectus or any amendment or supplement thereto, any issuer free writing prospectus as defined

in Rule 433(h) under the Securities Act, any Company information that the Company has filed, or is required to file, pursuant to Rule

433(d) under the Securities Act, any “road show” as defined in Rule 433(h) under the Securities Act (a “road show”),

the Prospectus or any amendment or supplement thereto, or any Testing-the-Waters Communication, or arise out of, or are based upon, any

omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein

not misleading, except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any such untrue statement

or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to any Underwriter

furnished to the Company in writing by such Underwriter through the Representative expressly for use therein, it being understood and

agreed that the only such information furnished by the Underwriters through the Representative consists of the Underwriter Information.

(b)

Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, its directors, its officers who sign

the Registration Statement and each person, if any, who controls the Company within the meaning of either Section 15 of the Securities

Act or Section 20 of the Exchange Act to the same extent as the foregoing indemnity from the Company to such Underwriter, but only with

reference to information relating to such Underwriter furnished to the Company in writing by such Underwriter through the Representative

expressly for use in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any issuer free writing prospectus,

road show, or the Prospectus or any amendment or supplement thereto; it being understood and agreed that the only such information furnished

in writing by any such Underwriter through the Representative consists of the following information in the Prospectus under the caption

“Underwriters” (collectively, the “Underwriter Information”): (i) the concession and reallowance figures

appearing in the third paragraph (which, for the avoidance of doubt, starts with “The underwriters initially propose to offer…”);

and (ii) the information contained in the thirteenth paragraph relating to stabilizing transactions (which, for the avoidance of doubt,

starts with “In connection with this offering, the underwriters may engage in stabilizing transactions…”.

(c)

In case any proceeding (including any governmental investigation) shall be instituted involving any person in respect of which indemnity

may be sought pursuant to Section 8(a) or 8(b), such person (the “indemnified party”) shall promptly notify the person

against whom such indemnity may be sought (the “indemnifying party”) in writing and the indemnifying party, upon request

of the indemnified party, shall retain counsel reasonably satisfactory to the indemnified party to represent the indemnified party and

any others the indemnifying party may designate in such proceeding and shall pay the reasonably incurred fees and disbursements of such

counsel related to such proceeding. In any such proceeding, any indemnified party shall have the right to retain its own counsel, but

the fees and expenses of such counsel shall be at the expense of such indemnified party unless (i) the indemnifying party and the indemnified

party shall have mutually agreed to the retention of such counsel or (ii) the named parties to any such proceeding (including any impleaded

parties) include both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be

inappropriate due to actual or potential differing interests between them. It is understood that the indemnifying party shall not, in

respect of the legal expenses of any indemnified party in connection with any proceeding or related proceedings in the same jurisdiction,

be liable for the fees and expenses of more than one separate firm (in addition to any local counsel) for all such indemnified parties

and that all such fees and expenses shall be reimbursed as they are incurred. Such firm shall be designated in writing by the Representative,

in the case of parties indemnified pursuant to Section 8(a), and by the Company, in the case of parties indemnified pursuant to Section

8(b). The indemnifying party shall not be liable for any settlement of any proceeding effected without its written consent, but if settled

with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party

from and against any loss or liability by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time

an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as

contemplated by the second and third sentences of this paragraph, the indemnifying party agrees that it shall be liable for any settlement

of any proceeding effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by such

indemnifying party of the aforesaid request and (ii) such indemnifying party shall not have reimbursed the indemnified party in accordance

with such request prior to the date of such settlement. No indemnifying party shall, without the prior written consent of the indemnified

party, effect any settlement of any pending or threatened proceeding in respect of which any indemnified party is or could have been

a party and indemnity could have been sought hereunder by such indemnified party, unless such settlement includes an unconditional release

of such indemnified party from all liability on claims that are the subject matter of such proceeding.

(d)

To the extent the indemnification provided for in Section 8(a) or 8(b) is unavailable to an indemnified party or insufficient in

respect of any losses, claims, damages or liabilities referred to therein, then each indemnifying party under such paragraph, in

lieu of indemnifying such indemnified party thereunder, shall contribute to the amount paid or payable by such indemnified party as

a result of such losses, claims, damages or liabilities (i) in such proportion as is appropriate to reflect the relative benefits

received by the Company on the one hand and the Underwriters on the other hand from the offering of the Shares or (ii) if the

allocation provided by clause 8(d)(i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not

only the relative benefits referred to in clause 8(d)(i) above but also the relative fault of the Company on the one hand and of the

Underwriters on the other hand in connection with the statements or omissions that resulted in such losses, claims, damages or

liabilities, as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand

and the Underwriters on the other hand in connection with the offering of the Shares shall be deemed to be in the same respective

proportions as the net proceeds from the offering of the Shares (before deducting expenses) received by the Company and the total

underwriting discounts and commissions received by the Underwriters, in each case as set forth in the table on the cover of the

Prospectus, bear to the aggregate Public Offering Price. The relative fault of the Company on the one hand and the Underwriters on

the other hand shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material

fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or by the

Underwriters and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such

statement or omission. The Underwriters’ respective obligations to contribute pursuant to this Section 8 are several in

proportion to the respective number of Securities they have purchased hereunder, and not joint.

(e)

The Company and the Underwriters agree that it would not be just or equitable if contribution pursuant to this Section 8 were

determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other

method of allocation that does not take account of the equitable considerations referred to in Section 8(d). The amount paid or

payable by an indemnified party as a result of the losses, claims, damages and liabilities referred to in Section 8(d) shall be

deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such indemnified

party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this Section 8, no

Underwriter shall be required to contribute any amount in excess of the amount by which the total price at which the Shares

underwritten by it and distributed to the public were offered to the public exceeds the amount of any damages that such Underwriter

has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person

guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Shares Act) shall be entitled to contribution

from any person who was not guilty of such fraudulent misrepresentation. The remedies provided for in this Section 8 are not

exclusive and shall not limit any rights or remedies which may otherwise be available to any indemnified party at law or in

equity.

(f)

The indemnity and contribution provisions contained in this Section 8 and the representations, warranties and other statements of

the Company contained in this Agreement shall remain operative and in full force and effect regardless of (i) any termination of

this Agreement, (ii) any investigation made by or on behalf of any Underwriter, the directors, officers, employees and agents of the

Underwriters, any person controlling any Underwriter or any affiliate of any Underwriter or by or on behalf of the Company, its

officers or directors or any person controlling the Company and (iii) acceptance of and payment for any of the Shares.

Termination. The Underwriters may terminate this Agreement at their discretion by notice given by the Representative to the Company,

if after the execution and delivery of this Agreement and prior to or on the Closing Date (i) trading generally shall have been suspended

or materially limited on, or by, as the case may be, any of the New York Stock Exchange, the NYSE American, the Nasdaq Capital Market,

the Nasdaq Global Select Market, the Chicago Board of Options Exchange, the Chicago Mercantile Exchange or the Chicago Board of Trade,

(ii) trading of any securities of the Company shall have been suspended on any exchange or in any over-the-counter market, (iii) a material

disruption in securities settlement, payment or clearance services in the United States shall have occurred, (iv) any moratorium on commercial

banking activities shall have been declared by Federal or New York State authorities or (v) there shall have occurred any outbreak or

escalation of hostilities, or any change in financial markets or any calamity or crisis that, in the judgment of the Representative,

is material and adverse and which, singly or together with any other event specified in this clause (v), makes it, in the judgment of

the Representative, impracticable or inadvisable to proceed with the offer, sale or delivery of the Shares on the terms and in the manner

contemplated in the Time of Sale Prospectus or the Prospectus.

10.

Effectiveness; Defaulting Underwriters. This Agreement shall become effective upon the execution and delivery hereof by the parties

hereto.

If,

on the Closing Date, any one or more of the Underwriters shall fail or refuse to purchase Securities that it has or they have agreed

to purchase hereunder on such date, and the aggregate number of Securities which such defaulting Underwriter or Underwriters agreed but

failed or refused to purchase is not more than one-tenth of the aggregate number of the Shares to be purchased on such date, the other

Underwriters shall be obligated severally in the proportions that the number of Securities set forth opposite their respective names

in Schedule I bears to the aggregate number of Securities set

forth opposite the names of all such non-defaulting Underwriters, or in such other proportions as the Representative may specify, to

purchase the Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase on such date; provided

that in no event shall the number of Securities that any Underwriter has agreed to purchase pursuant to this Agreement be increased pursuant

to this Section 10 by an amount in excess of one-ninth of such number of Securities without the written consent of such Underwriter.

If, on the Closing Date, any Underwriter or Underwriters shall fail or refuse to purchase Securities and the aggregate number of Securities

with respect to which such default occurs is more than one-tenth of the aggregate number of Securities to be purchased on such date,

and arrangements satisfactory to the Representative and the Company for the purchase of such Securities are not made within 36 hours

after such default, this Agreement shall terminate without liability on the part of any non-defaulting Underwriter or the Company. In

any such case either the Representative or the Company shall have the right to postpone the Closing Date, but in no event for longer

than seven days, in order that the required changes, if any, in the Registration Statement, in the Time of Sale Prospectus, in the Prospectus

or in any other documents or arrangements may be effected. Any action taken under this paragraph shall not relieve any defaulting Underwriter

from liability in respect of any default of such Underwriter under this Agreement.

this Agreement shall be terminated by the Underwriters, or any of them, because of any failure or refusal on the part of the Company

to comply with the terms or to fulfill any of the conditions of this Agreement, or if for any reason the Company shall be unable to perform

its obligations under this Agreement, the Company will reimburse the Underwriters or such Underwriters as have so terminated this Agreement

with respect to themselves, severally, for all out-of-pocket expenses (including the fees and disbursements of their counsel) reasonably

incurred by such Underwriters in connection with this Agreement or the offering contemplated hereunder.

11.

Entire Agreement. (a) This Agreement, together with any contemporaneous written agreements and any prior written agreements (to

the extent not superseded by this Agreement) that relate to the offering of the Shares, represents the entire agreement between the Company

and the Underwriters with respect to the preparation of any preliminary prospectus, the Time of Sale Prospectus, the Prospectus, the

conduct of the offering, and the purchase and sale of the Shares.

(b)

The Company acknowledges that in connection with the offering of the Shares including with respect to the determination of the Public

Offering Price and any related discounts and commissions: (i) the Underwriters have acted at arm’s length, are not agents of, and

owe no fiduciary duties to, the Company or any other person, (ii) the Underwriters owe the Company only those duties and obligations

set forth in this Agreement and prior written agreements (to the extent not superseded by this Agreement), if any, (iii) the Underwriters

may have interests that differ from those of the Company, and (iv) none of the activities of the Underwriters in connection with the

transactions contemplated herein constitutes a recommendation, investment advice, or solicitation of any action by the Underwriters with

respect to any entity or natural person. The Company waives to the full extent permitted by applicable law any claims it may have against

the Underwriters arising from an alleged breach of fiduciary duty in connection with the offering of the Shares.

12.

Recognition of the U.S. Special Resolution Regimes. (a) In the event that any Underwriter that is a Covered Entity becomes subject

to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation

in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution

Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United

States.

(b)

In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding

under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted

to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement

were governed by the laws of the United States or a state of the United States.

For

purposes of this Section a “BHC Act Affiliate” has the meaning assigned to the term “affiliate” in, and

shall be interpreted in accordance with, 12 U.S.C. § 1841(k). “Covered Entity” means any of the following: (i)

a “covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b); (ii) a “covered

bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or (iii) a “covered FSI”

as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b). “Default Right” has the

meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable.

“U.S. Special Resolution Regime” means each of (i) the Federal Deposit Insurance Act and the regulations promulgated

thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.

13.

Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of

which together shall constitute one and the same instrument. Delivery of an executed copy of this Agreement by one party to the other

may be made by facsimile or other electronic transmission (including pdf or any electronic signature complying with the U.S. federal

ESIGN Act of 2000, e.g., www.docusign.com or www.echosign.com) or other transmission method and any counterpart so delivered shall be

deemed to have been duly and validly delivered and be valid and effective for all purposes.

14.

Applicable Law. This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York.

15.

Headings. The headings of the sections of this Agreement have been inserted for convenience of reference only and shall not be

deemed a part of this Agreement.

16.

Notices. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed

or transmitted by any standard form of telecommunication and shall only be effective upon receipt. Notices to the Underwriters shall

be delivered, mailed or sent to Morgan Stanley & Co. LLC, at 1585 Broadway, New York, New York 10036, Attention: Equity Syndicate

Desk, with a copy to the Legal Department. Notices to the Company shall be delivered, mailed or sent to Immix Biopharma, Inc. 11400 West

Olympic Boulevard, Suite 200, Los Angeles, California, 90064, attention: Ilya Rachman and Gabriel Morris.

Very truly yours,

IMMIX

BIOPHARMA, INC.

By:

/s/

Ilya Rachman

Name:

Ilya Rachman

Title:

Chief Executive Officer

[Signature

Page – Underwriting Agreement]

Accepted

as of the date hereof

Morgan

Stanley & Co. LLC

Acting

severally on behalf of itself and the several Underwriters named in Schedule I hereto.

By:

MORGAN

STANLEY & CO. LLC

By:

/s/

Chirag D. Surti

Name:

Chirag D. Surti

Title:

Executive Director

[Signature

Page – Underwriting Agreement]

Schedule

Underwriter

Number

of Shares

To Be Purchased

Morgan Stanley & Co. LLC

8,389,262

BofA Securities, Inc.

3,355,705

LifeSci Capital LLC

2,013,423

Mizuho Securities USA

LLC

1,845,638

Needham & Company,

LLC

1,174,496

Total:

16,778,524

I-1

Schedule

Time

of Sale Prospectus

a. Pricing

Disclosure Package

Free

writing prospectus dated May 21, 2026

b. Pricing

Information Provided Orally by Underwriters

Public

Offering Price per Share: $8.94

Number

of Shares: 16,778,524

II-1

EXHIBIT

FORM

OF LOCK-UP AGREEMENT

May [●],

2026

Morgan

Stanley & Co. LLC

c/o

Morgan Stanley & Co. LLC

1585

Broadway

New

York, New York 10036

Ladies

and Gentlemen:

The

undersigned understands that Morgan Stanley & Co. LLC (“Morgan Stanley”) proposes to enter into an Underwriting

Agreement (the “Underwriting Agreement”) with Immix Biopharma, Inc. (“Immix” or the “Company”),

a Delaware corporation (the “Company”) providing for the public offering (the “Public Offering”)

by the several underwriters listed on Schedule I to the Underwriting Agreement, including Morgan Stanley (the “Underwriters”),

of shares (the “Shares”) of the common stock, par value $0.0001 per share, of the Company (the “Common Stock”).

To the extent that there are no additional Underwriters listed on Schedule I to the Underwriting Agreement other than Morgan Stanley,

the term Underwriters shall mean the singular as the context requires.

induce the Underwriters that may participate in the Public Offering to continue their efforts in connection with the Public Offering,

the undersigned hereby agrees that, without the prior written consent of Morgan Stanley on behalf of the Underwriters, it will not, and

will not publicly disclose an intention to, during the period commencing on the date hereof and ending 90 days after the date of the

final prospectus supplement (the “Restricted Period”) relating to the Public Offering (the “Prospectus”),

(1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any

option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock beneficially

owned (as such term is used in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)),

by the undersigned or any other securities so owned convertible into or exercisable or exchangeable for Common Stock (such options, rights

warrants or other securities, collectively, “Derivative Instruments”) or (2) enter into any swap or other arrangement

that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction

described in clause (1) or (2) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise. Except

as set forth under clauses (e), (f), (h) and (i) below, the undersigned represents and warrants that the undersigned is not, and has

not caused or directed any of its affiliates to be or become, currently a party to any agreement or arrangement that provides for, is

designed to or which reasonably could be expected to lead to or result in any transfer of Common Stock or Derivative Instruments beneficially

owned by the undersigned. The first sentence of this paragraph shall not apply to:

(a) transfers

of shares of Common Stock or any security convertible into or exercisable or exchangeable

for Common Stock (i) as a bona fide gift or charitable contribution, (ii) to an immediate

family member of the undersigned or a trust for the direct or indirect benefit of the undersigned

or one or more immediate family member of the undersigned (for purposes of this letter agreement,

“immediate family member” shall mean any relationship by blood, marriage

or adoption, not more remote than first cousin), (iii) if the undersigned is a trust, to

a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust, (iv)

if the undersigned is a corporation, partnership, limited

liability company, trust or other business entity, to another corporation, partnership,

limited liability company, trust or other business entity that is an affiliate (as defined

in Rule 405 promulgated under the Securities Act of 1933, as amended) of the undersigned,

or to any investment fund or other entity controlled or managed by the undersigned or affiliates

of the undersigned, or as part of a distribution, transfer or disposition without consideration

by the undersigned to its stockholders, current or former partners (general or limited),

members, beneficiaries or other equity holders, or to the estates of any such stockholders,

partners, members, beneficiaries or other equity holders, (v) by will, other testamentary

document or intestate succession to the legal representative, heir, beneficiary or a member

of the immediate family of the undersigned, or (vi) to a nominee or custodian of a person

or entity to whom a disposition or transfer would be permissible under clauses (a)(i) through

(a)(v); provided that (x) in the case of any transfer or distribution pursuant to

this clause (a), each transferee shall sign and deliver a lock-up letter substantially in

the form of this letter agreement and such transfer shall not involve a disposition of value,

(y) in the case of any transfer or distribution pursuant to clause (a)(iv), no filing by

any party (donor, done, devisee, transferor, transferee, distributer or distribute) under

Section 16(a) of the Exchange Act, or other public announcement shall be required or shall

be made voluntarily in connection with such transfer or distribution (other than a filing

on a Form 5 made after the expiration of the Restricted Period), and (z) in the case of any

transfer or distribution pursuant to clause (a)(i), (ii), (iii), (v) and (vi), it shall be

a condition to such transfer that no public filing, report or announcement shall be voluntarily

made, and if any filing under Section 16(a) of the Exchange Act, or other public filing,

report or announcement reporting a reduction in beneficial ownership of shares of Common

Stock in connection with such transfer or distribution shall be legally required during the

Restricted Period, such filing, report or announcement shall clearly indicate in the footnotes

thereto the nature and conditions of such transfer;

A-1

(b) transfers

of shares of Common Stock or any securities convertible into or exercisable or exchangeable

for Common Stock that occur by operation of law pursuant to a qualified domestic order or

in connection with a divorce settlement, provided that no public filing, report or

announcement shall be voluntarily made, and any filing required to be made under Section

16(a) of the Exchange Act shall clearly indicate in the footnotes thereto that such transfer

is pursuant to a qualified domestic order or in connection with a divorce settlement;

of shares of Common Stock or any securities convertible into or exercisable or exchangeable

for Common Stock to the Company pursuant to agreements under which the Company has the option

to repurchase such shares or securities upon termination of service of the undersigned or

a right of first refusal with respect to transfers of such shares, provided that such

agreements are described in the Company’s filings with the Securities and Exchange

Commission (the “SEC”) and provided, further that no public filing,

report or announcement shall be voluntarily made, and any filing required to be made under

Section 16(a) of the Exchange Act shall clearly indicate in the footnotes thereto that such

transfer is pursuant to the circumstances described in this clause (c);

(d) the

exercise of any stock option by or the vesting and settlement of any restricted stock unit

of the undersigned outstanding as of the date hereof or that was granted under a stock incentive

plan or stock purchase plan described in the Company’s filings with the SEC, provided

that the shares received upon exercise or vesting or settlement shall continue to be subject

to this letter agreement and provided, further that any filing required to be made

under Section 16(a) of the Exchange Act shall clearly indicate in the footnotes thereto that

the filing relates to the exercise of a stock option or settlement of a restricted stock

unit, that no shares were sold by the reporting person and that the shares received upon

exercise of the stock option or settlement of the restricted stock unit are subject to the

terms of this letter agreement;

(e) transfers

of shares of Common Stock to the Company upon the exercise of stock options outstanding as

of the date hereof or that were granted pursuant to a stock incentive plan or stock purchase

plan described in the Company’s filings with the SEC, on a “cashless” or

“net exercise” basis, provided that the shares received upon exercise

shall continue to be subject to this letter agreement and provided, further that no

public filing, report or announcement shall be voluntarily made, and any filing required

to be made under Section 16(a) of the Exchange Act shall clearly indicate in the footnotes

thereto that the filing relates to the “cashless” or “net” exercise

of a stock option, that no shares were sold by the reporting person and that the shares received

upon exercise of the stock option are subject to the terms of this letter agreement;

A-2

(f) transfers

of shares of Common Stock to the Company, or the withholding of shares of Common Stock by

the Company, in connection with a vesting event or subsequent settlement (as applicable)

of restricted stock awards or restricted stock units, in each case which are outstanding

as of the date hereof or were granted pursuant to a stock incentive plan or stock purchase

plan described in the Company’s filings with the SEC, to cover tax withholding obligations

or the payment of taxes, including estimated taxes, due in connection with the vesting event,

provided that no public filing, report or announcement shall be voluntarily made,

and any filing required to be made under Section 16(a) of the Exchange Act shall clearly

indicate in the footnotes thereto that the purpose of such transfer is to cover such tax

withholding obligations or the payment of taxes due in connection with the vesting event;

(g) transfers

of shares pursuant to a bona fide third-party tender offer, merger, consolidation, other

similar transaction or series of related transactions involving a Change of Control (as defined

below) of the Company (including, without limitation, entering into any lock-up, voting or

similar agreement pursuant to which the undersigned may agree to transfer, sell, tender or

otherwise dispose of Common Stock or other securities in connection with any such transaction,

or vote any securities in favor of any such transaction), provided that in the event that

such Change of Control is not completed, the undersigned’s shares shall remain subject

to this letter agreement and title to the undersigned’s shares shall remain with the

undersigned;

(h) transfers

of shares pursuant to a trading plan established pursuant to Rule 10b5-1 under the Exchange

Act (a “10b5-1 Plan”) that has been disclosed to the Underwriters and

entered into by the undersigned prior to the date of this letter agreement, provided

that no public filing, report or announcement shall be voluntarily made, and any filing required

to be made under Section 16(a) of the Exchange Act shall clearly indicate in the footnotes

thereto that such transfer is pursuant to a 10b5-1 Plan; or

(i) the

establishment or amendment of a 10b5-1 Plan for the transfer of shares of Common Stock, provided

that (i) such plan does not provide for the transfer of Common Stock during the Restricted

Period and (ii) to the extent a public announcement or filing under the Exchange Act, if

any, is required of or voluntarily made by or on behalf of the undersigned or the Company

regarding the establishment of such plan, such announcement or filing shall include a statement

to the effect that no transfer of Common Stock may be made under such plan during the Restricted

Period.

addition, the undersigned agrees that, without the prior written consent of Morgan Stanley on behalf of the Underwriters, it will not,

during the Restricted Period, make any demand for or exercise any right with respect to, the registration of any shares of Common Stock

or any security convertible into or exercisable or exchangeable for Common Stock.

The

undersigned also agrees and consents to the entry of stop transfer instructions with the Company’s transfer agent and registrar

against the transfer of the undersigned’s shares of Common Stock except in compliance with the foregoing restrictions. “Change

of Control” means the transfer (whether by tender offer, merger, consolidation, other similar transaction or series of related

transactions), in one transaction or a series of related transactions approved by the Company’s board of directors, to a person

or group of affiliated persons, of the Company’s voting securities if, after such transfer, such person or group of affiliated

persons would hold more than 50% of the outstanding voting securities of the Company (or the surviving entity) provided that,

for the avoidance of doubt, the Public Offering shall not constitute a Change of Control.

A-3

the undersigned is not a natural person, the undersigned represents and warrants that no single natural person, entity or “group”

(within the meaning of Section 13(d)(3) of the Exchange Act), other than a natural person, entity or “group” (as described

above) that has executed a lock-up agreement in substantially the same form as this letter agreement, beneficially owns, directly or

indirectly, 50% or more of the common equity interests, or 50% or more of the voting power, in the undersigned.

The

undersigned understands that the Company and the Underwriters are relying upon this letter agreement in proceeding towards the consummation

of the Public Offering. The undersigned further understands that this letter agreement is irrevocable and shall be binding upon the undersigned’s

heirs, legal representatives, successors and assigns.

The

undersigned acknowledges and agrees that the Underwriters have not provided any recommendation or investment advice nor have the Underwriters

solicited any action from the undersigned with respect to the Public Offering and the undersigned has consulted their own legal, accounting,

financial, regulatory and tax advisors to the extent deemed appropriate. The undersigned further acknowledges and agrees that, although

the Underwriters may provide certain Regulation Best Interest and Form CRS disclosures or other related documentation to you in connection

with the Public Offering, the Underwriters are not making a recommendation to you to participate in the Public Offering or sell any Shares

at the price determined in the Public Offering, and nothing set forth in such disclosures or documentation is intended to suggest that

any Underwriter is making such a recommendation.

This

letter agreement shall automatically terminate and the undersigned shall be released from all obligations under this letter agreement

upon the earliest to occur, if any, of (i) the date the Company, on the one hand, or the Underwriters, on the other hand, informs the

other in writing, prior to the execution of the Underwriting Agreement, that it has determined not to proceed with the Public Offering,

(ii) the date the Underwriting Agreement is terminated (other than the provisions thereof which survive termination) prior to payment

for and delivery of the securities to be sold thereunder, and (iii) May 31, 2026, if the Underwriting Agreement has not been executed

by such date (which date may be extended for an additional three months by the Company upon written notice to the undersigned).

Whether

or not the Public Offering actually occurs depends on a number of factors, including market conditions. Any Public Offering will only

be made pursuant to an Underwriting Agreement, the terms of which are subject to negotiation between the Company and the Underwriters.

This

letter agreement and any claim, controversy or dispute arising under or related to this agreement shall be governed by and construed

in accordance with the laws of the State of New York, without regard to the conflict of laws principles thereof.

Electronic

signatures complying with the New York Electronic Signatures and Records Act (N.Y. State Tech. §§ 301-309), as amended from

time to time, or other applicable law will be deemed original signatures for purposes of this letter agreement. Transmission by telecopy,

electronic mail or other transmission method of an executed counterpart of this letter agreement will constitute due and sufficient delivery

of such counterpart.

[Signature

Page Follows]

A-4

Very

truly yours,

(Name)

(Address)

A-5

EX-5.1

Filename: ex5-1.htm · Sequence: 3

Exhibit

5.1

1271

Avenue of the Americas | New York, NY 10020

blankrome.com

May

21, 2026

The

Board of Directors

Immix

Biopharma, Inc.

11400

West Olympic Blvd., Suite 200

Los

Angeles, CA 90064

Ladies

and Gentlemen:

have acted as securities counsel to Immix Biopharma, Inc., a Delaware corporation (the “Company”), in connection with the

issuance and sale of 16,778,524 shares (the “Shares”) of common stock of the Company, par value $0.0001 per share (the “Common

Stock). The Shares are being issued in a registered direct offering and are being registered pursuant to a registration statement on

Form S-3 (File No. 333-292665) (the “Registration Statement”) filed on January 9, 2026 by the Company with the Securities

and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”),

which was declared effective by the Commission on January 22, 2026, a base prospectus included in the Registration Statement at the time

it originally became effective (the “Base Prospectus”), and a prospectus supplement dated May 21, 2026 filed with the Commission

on May 21, 2026 pursuant to Rule 424(b)(5) under the Securities Act (the “Prospectus Supplement” and, together with the Base

Prospectus, the “Prospectus”). The Shares are being issued pursuant to an underwriting agreement, dated May 21, 2026, by

and between the Company and Morgan Stanley & Co. LLC, as representative of the several underwriters named therein (the “Underwriting

Agreement”).

This

opinion is being furnished in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act, in connection

with the Registration Statement, and no opinion is expressed or may be implied herein as to any matter pertaining to the contents of

the Registration Statement, the Prospectus, or Prospectus Supplement.

rendering the opinions set forth herein, we have examined originals or copies, certified or otherwise identified to our satisfaction,

of (i) the Registration Statement and all exhibits thereto; (ii) the Prospectus; (iii) the Underwriting Agreement; (iv) resolutions adopted

by the Board of Directors of the Company (the “Board”) and a pricing committee of the Board; (v) the third amended and restated

certificate of incorporation of the Company (the “Certificate of Incorporation”); (vi) the amended and restated bylaws of

the Company; and (vii) such other corporate records, agreements, certificates, including, but not limited to, certificates or comparable

documents of public officials and of officers and representatives of the Company, statutes and other instruments and documents as we

considered relevant and necessary as a basis for the opinions hereinafter expressed.

rendering this opinion, we have assumed, without inquiry, the legal capacity of all natural persons, the genuineness of all signatures

on all documents examined by us, the authenticity of all documents submitted to us as originals, the conformity to the original documents

of all documents submitted to us as copies and the authenticity of the originals of such latter documents. We have also assumed that

the books and records of the Company are maintained in accordance with proper corporate procedures. As to any facts material to our opinions,

we have relied upon the aforesaid agreements, instruments, certificates, documents and records noted above (including the representations,

warranties, covenants and agreements of the Company given in, pursuant to or in connection with the agreements, instruments, certificates,

documents and records noted above).

The

Board of Directors

Immix

Biopharma, Inc.

May

21, 2026

Page

Based

upon and subject to the foregoing, we are of the opinion that the Shares have been duly authorized for issuance and, when issued, delivered

and paid for in accordance with the terms of the Underwriting Agreement, will be validly issued, fully paid and nonassessable.

are opining solely on all applicable statutory provisions of Delaware corporate law, including the rules and regulations underlying those

provisions, all applicable provisions of the Delaware Constitution and all applicable judicial and regulatory determinations. This opinion

is limited to the laws of the State of Delaware as in effect on the date hereof and we express no opinion with respect to the laws of

any other jurisdiction.

hereby consent to the filing of this opinion as Exhibit 5.1 to a Current Report on Form 8-K that will be filed by the Company and incorporated

by reference into the Registration Statement and to the reference to our firm under the caption “Legal Matters” in the Prospectus.

In giving our consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the

Securities Act or the rules and regulations of the Commission thereunder.

Very

truly yours,

/s/

BLANK ROME LLP

BLANK

ROME LLP

EX-99.1

Filename: ex99-1.htm · Sequence: 4

Exhibit 99.1

Immix

Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock

LOS

ANGELES, CA, May 21, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We”

or “Us” or “IMMX”), a global leader in AL Amyloidosis, today announced the pricing of an underwritten registered

offering of 16,778,524 shares of its common stock at a price to the public of $8.94 per share. The gross proceeds to Immix

from the offering, before deducting the underwriting discounts, commissions and other offering expenses, are expected to be $150

million. The offering is expected to close on or about May 22, 2026, subject to the satisfaction of customary closing conditions.

Immix

intends to use the net proceeds from this offering to fund NXC-201 development, working capital and general corporate purposes. Immix

believes that the net proceeds from the offering, together with its existing cash and cash equivalents, will be sufficient to meet the

Company’s operational needs into mid-2028.

Morgan

Stanley is acting as the lead book-running manager and BofA Securities is acting as book-running manager for the offering. LifeSci Capital, Mizuho and Needham & Company are acting as co-lead managers for the offering.

The

securities in the registered offering are being offered and sold pursuant to a “shelf” registration statement on Form S-3

(File No. 333-292665), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on

January 9, 2026, and declared effective on January 22, 2026. A prospectus supplement and accompanying prospectus describing the terms

of the registered offering will be filed with the SEC and will be available on its website at www.sec.gov. Copies of the prospectus supplement

and the accompanying prospectus relating to the offering, when available, may also be obtained from: Morgan Stanley & Co. LLC, attention:

Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by phone: 1-866-718-1649 or by email: prospectus@morganstanley.com.

This

press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor

shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful

prior to registration or qualification under the securities laws of any such state or jurisdiction.

About

Immix Biopharma, Inc.

Immix

Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune

system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ

failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201

with a “digital filter” that is designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize

and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory

AL Amyloidosis NEXICART-2 (NCT06097832), with a potentially registrational design. NXC-201 has been awarded Breakthrough Therapy Designation

(BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.

Forward

Looking Statements

This

press release contains forward-looking statements within the meaning of the federal securities laws. Words such as “may,”

“might,” “will,” “should,” “believe,” “expect,” “anticipate,”

“estimate,” “continue,” “predict,” “forecast,” “project,” “plan,”

“intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements.

These forward-looking statements are based upon current estimates and assumptions and include statements relating to the offering, including

the timing of the closing of the offering, the anticipated use of proceeds therefrom, the Company’s cash runway, the potential

benefits of the Company’s product candidate CAR-T NXC-201 and the timing and results related to clinical trials, including

planned trials. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any

such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements

are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially

from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could

cause actual results to differ materially from current expectations include, among others, risks and uncertainties relating to market

conditions; the completion of the proposed offering on the anticipated terms or at all; the risk that the estimates for the number of

patients in the U.S. with relapsed/refractory AL Amyloidosis and the market size are not accurate; the risk that further data from the

ongoing U.S. Phase 1b/2 clinical trial and ex-U.S. Phase 1b/2a clinical trial for CAR-T NXC-201 will not be favorably consistent with

the data readouts to date; that no drug product developed by the Company has received FDA pre-market approval or otherwise been incorporated

into a commercial drug product; that success in early phases of pre-clinical and clinicals trials do not ensure later clinical trials

will be successful; and those other risks disclosed in the section “Risk Factors” included in the Company’s Annual

Report on Form 10-K for the fiscal year ended December 31, 2025 and other periodic or current reports subsequently filed with the Securities

and Exchange Commission. These reports are available at www.sec.gov. Immix Biopharma cautions that the foregoing list of important factors

is not complete. Immix Biopharma cautions readers not to place undue reliance on any forward-looking statements. Immix Biopharma does

not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated

events as they occur, except as required by law. If we update one or more forward-looking statements, no inference should be drawn that

we will make additional updates with respect to those or other forward-looking statements.

Contacts

Mike

Moyer

LifeSci Advisors

mmoyer@lifesciadvisors.com

Company

Contact

irteam@immixbio.com

GRAPHIC

Filename: ex5-1_001.jpg · Sequence: 5

Binary file (2544 bytes)

Download ex5-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 21

v3.26.1

Cover

May 21, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 21, 2026

Entity File Number

001-41159

Entity Registrant Name

IMMIX

BIOPHARMA, INC.

Entity Central Index Key

0001873835

Entity Tax Identification Number

45-4869378

Entity Incorporation, State or Country Code

Entity Address, Address Line One

11400

West Olympic Blvd.

Entity Address, Address Line Two

Suite 200

Entity Address, City or Town

Los

Angeles

Entity Address, State or Province

Entity Address, Postal Zip Code

90064

City Area Code

(310)

Local Phone Number

651-8041

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value of $0.0001 per share

Trading Symbol

IMMX

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration